{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:42:49Z","timestamp":1788586969424,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3165,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>The role of antivirals in patients with acute viral hepatitis B (AVH-B) has not been evaluated in controlled trials. The aim of this study was to evaluate the efficacy of lamivudine in patients with AVH-B. AVH-B patients with serum bilirubin of more than 5 mg\/dL were randomized to receive either 100 mg of lamivudine daily for 3 months (group 1,<\/jats:bold>\n                      <jats:bold>n<\/jats:bold>\n                      <jats:bold>= 31) or placebo (group 2,<\/jats:bold>\n                      <jats:bold>n<\/jats:bold>\n                      <jats:bold>= 40). Patients were considered to have severe AVH-B if they fulfilled 2 of 3 criteria: (1) hepatic encephalopathy; (2) serum bilirubin \u2265 10.0 mg\/dL; and (3) international normalized ratio (INR) \u2265 1.6. At week 4, HBV DNA levels were significantly lower (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.037) in group 1 (median: 3.6721 log copies\/mL) than group 2 (median: 4.2721 log copies\/mL). Thereafter, HBV DNA levels were comparable in the 2 groups. The improvement in serum bilirubin, ALT, and INR values was similar in the 2 groups. Twenty-two patients (71%) in group 1 and 25 patients (62.5%) in group 2 had severe AVH-B. Results were similar when patients with severe AVH-B were analyzed separately. After 12 and 18 months, 93.5% and 92.5%, respectively, of patients in the lamivudine group and 96.7% and 97.5%, respectively, of patients in the placebo group lost HBsAg. There were no deaths in either group. After 1 year, 21 patients (67.7%) in group 1 and 34 patients (85%) in group 2 developed protective anti-HBs titers (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.096). All HBeAg-positive patients in both groups lost e antigen and anti-HBe developed in 71% and 87.5% of patients in groups 1 and 2, respectively (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.132).<\/jats:bold>\n                      <jats:bold>Conclusion:<\/jats:bold>\n                      <jats:bold>Though lamivudine causes a greater decrease in levels of HBV DNA, it does not cause significantly greater biochemical and clinical improvement as compared to placebo in patients with acute hepatitis B. Hepatology 2007;45:97\u2013101.)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.21486","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T17:54:22Z","timestamp":1166810062000},"page":"97-101","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":164,"title":["A randomized controlled trial of lamivudine to treat acute hepatitis B"],"prefix":"10.1097","volume":"45","author":[{"given":"M.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Monga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hissar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20241202","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/jhep.2003.50171","article-title":"Longterm histologic and virologic outcomes of acute selflimited hepatitis B.","volume":"37","author":"Yuki","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R2-14-20241202","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199512213332501","article-title":"A preliminary trial of lamivudine for chronic hepatitis B infection.","volume":"333","author":"Dienstag","year":"1995","journal-title":"N Engl J Med"},{"key":"R3-14-20241202","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0168-8278(98)80127-X","article-title":"L, Belli L, Milandri G L, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation.","volume":"29","author":"Andreone","year":"1998","journal-title":"J Hepatol"},{"key":"R4-14-20241202","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/jlts.2002.35555","article-title":"Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.","volume":"8","author":"Castells","year":"2002","journal-title":"Liver Transpl"},{"key":"R5-14-20241202","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM200010123431513","article-title":"Lamivudine in the treatment of acute hepatitis B.","volume":"343","author":"Reshef","year":"2000","journal-title":"N Engl J Med"},{"key":"R6-14-20241202","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1386-6346(02)00009-8","article-title":"Effectiveness and longterm outcome of lamivudine therapy for acute hepatitis B.","volume":"24","author":"Torii","year":"2002","journal-title":"Hepatol Res"},{"issue":"Suppl","key":"R7-14-20241202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-8278(03)80682-7","article-title":"Lamivudine in severe acute viral B hepatitis.","volume":"38","author":"Abagiu","year":"2003","journal-title":"J Hepatol"},{"key":"R8-14-20241202","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1478-3231.2004.0983.x","article-title":"Lamivudine treatment for acute severe hepatitis B: a pilot study.","volume":"24","author":"SchmilovitzWeiss","year":"2004","journal-title":"Liver Int"},{"key":"R9-14-20241202","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jmv.10205","article-title":"Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.","volume":"68","author":"Wakil","year":"2002","journal-title":"J Med Virol"},{"key":"R10-14-20241202","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000089376","article-title":"Characterization of naturally occurring and Lamivudineinduced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India.","volume":"49","author":"Kazim","year":"2006","journal-title":"Intervirology"},{"key":"R11-14-20241202","first-page":"319A","article-title":"Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudinetreated hepatitis B patients.","volume":"28","author":"Atkins","year":"1988","journal-title":"HEPATOLOGY"},{"key":"R12-14-20241202","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-108-3-380","article-title":"Serologic markers with fulminant hepatitis in persons positive for hepatitis B surface antigen. A worldwide epidemiologic and clinical survey.","volume":"108","author":"Saracco","year":"1988","journal-title":"Ann Intern Med"},{"key":"R13-14-20241202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis.","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"R14-14-20241202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection.","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21486","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:07:35Z","timestamp":1733137655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21486","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1059700.511611","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}